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Abstract
Background: Steps towards the development of diagnostic criteria are needed for children with the
radiologically isolated syndrome to identify children at risk of clinical demyelination.
Objectives: To evaluate the 2005 and 2016 MAGNIMS magnetic resonance imaging criteria for dis-
semination in space for multiple sclerosis, both alone and with oligoclonal bands in cerebrospinal fluid
added, as predictors of a first clinical event consistent with central nervous system demyelination in
children with radiologically isolated syndrome.
Methods: We analysed an international historical cohort of 61 children with radiologically isolated
syndrome (18 years), defined using the 2010 magnetic resonance imaging dissemination in space
criteria (Ped-RIS) who were followed longitudinally (mean 4.2 4.7 years). All index scans also met the
2017 magnetic resonance imaging dissemination in space criteria.
Results: Diagnostic indices (95% confidence intervals) for the 2005 dissemination in space criteria, with
and without oligoclonal bands, were: sensitivity 66.7% (38.4–88.2%) versus 72.7% (49.8–89.3%); spe-
cificity 83.3% (58.6–96.4%) versus 53.9% (37.2–69.9%). For the 2016 MAGNIMS dissemination in
space criteria diagnostic indices were: sensitivity 76.5% (50.1–93.2%) versus 100% (84.6–100%); spe-
cificity 72.7% (49.8–89.3%) versus 25.6% (13.0–42.1%).
Conclusions: Oligoclonal bands increased the specificity of magnetic resonance imaging criteria in
children with Ped-RIS. Clinicians should consider testing cerebrospinal fluid to improve diagnostic
certainty. There is rationale to include cerebrospinal fluid analysis for biomarkers including oligoclonal
bands in planned prospective studies to develop optimal diagnostic criteria for radiologically isolated
syndrome in children.
Keywords: Radiologically isolated syndrome, multiple sclerosis, children
Date received: 1 September 2018; accepted: 15 January 2019
Introduction
Abnormalities suggestive of multiple sclerosis (MS)
are being detected with increasing frequency as
unexpected or incidental findings in individuals
without symptoms of MS who undergo magnetic
resonance imaging (MRI) scans for other reasons
(e.g. head trauma). This clinical scenario, termed
the radiologically isolated syndrome (RIS), has
been reported in adults and recently in children.1–6
Criteria for RIS in adults were proposed in 2009 and
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include the incidental detection of MRI abnormali-
ties that meet MRI criteria for dissemination in space
as outlined in the 2005 McDonald diagnostic criteria
for MS.7 In one study, approximately 34% of adults
who met this definition developed a first clinical
event consistent with MS within 5 years.2 There is
uncertainty as to whether the criteria for RIS in
adults should also be used for children.
We reported preliminary outcomes of the first lon-
gitudinal cohort study of children with RIS defined
using the 2010 McDonald criteria for dissemination
in space on MRI. All children also met the 2017
dissemination in space criteria on MRI at baseline
(Ped-RIS). A first clinical event consistent with cen-
tral nervous system demyelination (hereafter
referred to as a first clinical event) occurred in
42% of children (16/38) in a median of 2.0 years.3
We do not know which of the MRI criteria for dis-
semination in space, developed for a clinical diag-
nosis of MS, should be used to define RIS in
children or whether different criteria that might
also include laboratory tests such as oligoclonal
bands in cerebrospinal fluid (CSF) are needed. The
ideal diagnostic criteria for RIS would be sufficient-
ly sensitive to capture almost all children who later
develop a first clinical event while being sufficiently
specific to minimise the misclassification of children
who are actually at low risk (i.e. a ‘false positive’
result). Such criteria are critical to minimise mis-
diagnosis, but still identify high-risk children who
might benefit from interventions.
In the time since RIS was defined in adults, other
MRI criteria for dissemination in space have either
been adopted or proposed for the clinical diagnosis
of MS in symptomatic individuals. The 2010 and
2017 McDonald criteria have the least stringent
MRI criteria for dissemination in space and require
as few as two lesions if they are either located in
typical locations for MS in the brain (i.e. periven-
tricular, juxtacortical/cortical or infratentorial) or are
in the spinal cord.8,9 In 2016, the Magnetic
Resonance Imaging in MS (MAGNIMS) group pro-
posed criteria for dissemination in space on MRI.10
The major differences between the MAGNIMS cri-
teria and the 2010/2017 McDonald criteria include
the requirement that three or more periventricular
lesions, rather than one, be present and that lesions
detected in the optic nerve be counted. Both the
MAGNIMS and the 2017 McDonald criteria group
cortical lesions and juxtacortical lesions, with the
acknowledgement that the assessment of cortical
lesions may require specialised MRI sequences
such as double inversion recovery.
The 2017 McDonald criteria for MS allow the pres-
ence of unique oligoclonal bands in CSF to substi-
tute for either clinical or radiological dissemination
in time (but not space) in individuals with clinically
isolated syndrome.9 This change was based on stud-
ies in adults with clinically isolated syndrome.11–16
We reported that oligoclonal bands in CSF were
associated with the subsequent development of a
first clinical event in children with Ped-RIS.3
The objective of this study, conducted in our cohort
of children with Ped-RIS, was to evaluate the diag-
nostic performance of the 2005 and the MAGNIMS
2016 criteria for dissemination in space, both with
and without the addition of oligoclonal bands in
CSF, and their associations with the subsequent
development of a first clinical event.7,8,10
Methods
Participants and definitions
We identified a historical cohort of 61 children aged
18 years or less without any symptoms suggestive of
MS who had abnormalities on MRI found inciden-
tally that met the 2010 and 2017 MRI criteria
for dissemination in space for MS. Children were
identified between 1 December 1995 and 5
December 2017 at 22 collaborating MS centres
(Supplemental Table 1). A detailed clinical history
and neurological examination was performed for all
children. Tests to exclude other infectious, inflam-
matory, rheumatological or metabolic diseases were
performed based on local practice. Oligoclonal
bands were tested at the discretion of the treating
physician prior to a first clinical event, if one
occurred, using standard isoelectric focusing meth-
ods and were defined as present if there were two or
more bands present in the CSF, but not correspond-
ing serum.
First clinical events were diagnosed using
International Pediatric MS Study Group consensus
definitions.17 Institutional ethical approvals were
obtained at all sites. Written informed consent was
obtained from parents/guardians and children pro-
vided assent.
Neuroimaging
All children underwent MRI scans on either 1.5 T or
3 T MRI scanners. All brain/spinal cord MRI studies
included T1 and T2-weighted spin echo sequences in
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multiple planes of view (axial and sagittal, with cor-
onal images for brain studies), with and/or with-
out gadolinium.
MRI abnormalities were first identified by a board-
certified neuro-radiologist and then confirmed by
one or more MS specialist at each site who evaluated
the number of MRI lesions, the presence of MRI
lesions in specific locations (e.g. periventricular,
juxtacortical, infratentorial or spinal cord lesions),
and the presence of gadolinium-enhancing lesions
using standardised definitions.18 As sequences
highly sensitive to cortical lesions were not obtained,
such lesions could not be evaluated. In cases of dis-
agreement or uncertainty, two experienced MRI
raters (NM and DP), blinded to all clinical data,
made the final adjudication by consensus. We used
two methods to classify whether MRI scans met the
2005 and/or the MAGNIMS 2016 dissemination in
space criteria: (a) an experienced paediatric neurol-
ogist (NM) classified all scans and (b) a software
program that took individual subcriteria as inputs
and produced an output of whether patients met
each set of criteria. Both classification methods
were in 100% agreement.
Statistical analysis
We report means (standard deviations), and/or
medians with interquartile ranges (IQRs) for contin-
uous variables and frequencies (percentages) for cat-
egorical variables. We used Mann–Whitney U tests
(continuous variables) and Fisher’s exact tests (cat-
egorical variables) to determine the statistical signif-
icance of differences in baseline covariates (e.g. age,
sex or follow-up time) between children who either
did or did not develop a first clinical event.
The following statistical analyses were conducted
both using the complete case analysis of all observed
cases and, to handle missing data, using 30 multiply
imputed datasets by the fully conditional specifica-
tion method (aka chained equations).19–21 We used
standard methods to calculate predictive ability
(with 95% CIs) as measured by sensitivity, specific-
ity, positive predictive value (PPV), negative predic-
tive value (NPV) and accuracy as well as the overall
discriminant ability of individual and combinations
of predictors using receiver operator characteristic
(ROC) curves and area under the ROC curves
(AUC). As all index MRI scans met 2010 and
2017 dissemination in space criteria (i.e. there
were no true or false negative results), only PPV
was determined for these MRI criteria. In order to
assess the effect of follow-up time, we graphically
inspected time-dependent AUCs estimated using
inverse probability of censoring weighting.22,23
ROC curves based on models containing either the
2005 or the MAGNIMS 2016 criteria as individual
predictors were compared to the ROCs from models
with the addition of oligoclonal bands in CSF using
the non-parametric test of DeLong et al.24 To adjust
for the variable follow-up times in our cohort, we
used standard time-to-event survival analysis meth-
ods. We used unadjusted Cox proportional hazards
models to determine the associations between indi-
vidual components of the MRI dissemination in
space criteria (e.g. the presence of spinal cord
lesions) and the time to a first clinical event.
Multivariable models included predictors that were
statistically significant in unadjusted analyses, as
well as age (continuous in years), sex and any expo-
sure to disease-modifying agents for MS, which we
felt were clinically relevant variables. The propor-
tional hazards assumption was assessed using graph-
ical methods. We report hazard ratios (HRs) with
95% CIs. We considered two-sided P values less
than 0.05 as statistically significant. We used SAS
v. 9.4 (Cary, NC, USA) for all analyses.
Results
We screened 62 children, of whom one was exclud-
ed due to baseline MRI not being available to review
(neuro-radiologist report only). We therefore includ-
ed 61 children with Ped-RIS (Tables 1 and 2). As
expected, children who developed a first clinical
event had a longer time from index MRI to the
most recent clinic visit than those who did not
(mean 6.8 5.6 vs. 2.8 3.3 years, P=0.001) but
were otherwise similar. The most common reason
for obtaining initial neuroimaging was headache
(50.8%). Eight children were treated with a
disease-modifying agent for MS (five with interferon
beta-1a and three with glatiramer acetate) to try to
prevent a first clinical event. Two of the eight treated
children (25%) had spinal lesions detected on MRI
as compared to five out of 40 (12.5%) untreated
children who had spinal imaging (no significant dif-
ference, P=0.33). Five of the eight treated children
had spinal fluid tested and four out of five (80%)
had oligoclonal bands detected in the CSF as com-
pared to 15/29 (52%) of treated children in whom
CSF was analysed (no significant differ-
ence, P=0.43).
The number of children with Ped-RIS whose index
MRI scans also fulfilled the 2005 and 2016
MAGNIMS MRI criteria for dissemination in
space were 34 (55.7%) and 51 (83.6%),
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respectively. Gadolinium was administered for
brain MRIs in 39 children (63.9%) and spinal cord
imaging was obtained in 48 children (78.7%). There
was no association between age, sex, race and
whether children had either spinal cord imaging
obtained or gadolinium administered on index
brain MRIs.
CSF was tested for oligoclonal bands in 34 children
(55.7%, Tables 1 and 2) with a median of 25 days
from the index MRI (IQR 2–453 days), and in all
cases prior to a first clinical event if one occurred.
CSF was more likely to be obtained in girls than
boys (27/42 (64.3%) vs. 7/19 (36.8%), P=0.05).
Among the 39 children for whom gadolinium was
Table 1. Characteristics of children in the study.
Overall
N5 61
Children without
a clinical
neurological
event
N5 39
Children with
a clinical
neurological
event*
N5 22 P value
Age at first scan with RIS (years)
Mean (SD) 14.7 (2.4) 14.4 (2.3) 15.1 (2.5)
Median (IQR) 15.0 (13.1–16.4) 14.9 (13.1–16.3) 15.6 (13.1–17.1) 0.21†
Gender
Girls (%) 42 (68.9%) 24 (61.5%) 18 (81.8%)
Boys (%) 19 (31.2%) 15 (38.5%) 4 (18.2%) 0.10‡
Follow-up time (years)
Mean (SD) 4.2 (4.7) 2.8 (3.3) 6.8 (5.6)
Median (IQR) 2.4 (1.2–5.3) 1.6 (1.0–3.2) 5.1 (1.9–10.8) 0.001†
*Characteristics of a first clinical event included monofocal brainstem deficits (5), optic neuritis (4), transverse
myelitis (4), other monofocal deficits (6) and polyfocal deficits without encephalopathy (3). No child developed acute
disseminated encephalomyelitis.
†Wilcoxon sum rank test.
‡Fisher’s exact test.
RIS: radiologically isolated syndrome.
Table 2. Characteristics of children with cerebrospinal fluid tested.
Overall
N5 34
Children without
oligoclonal bands
N5 15
Children with
oligoclonal bands
N5 19 P value
Age at first scan with RIS (years)
Mean (SD) 14.7 (2.4) 14.9 (1.9) 14.6 (2.8)
Median (IQR) 15.0 (13.1–16.6) 15.0 (13.8–16.4) 15.0 (12.9–17.3) 1.00*
Gender
Girls (%) 27 (79.4%) 11 (73.3%) 16 (84.2%)
Boys (%) 7 (20.6%) 4 (26.7%) 3 (15.8%) 0.67†
Follow-up time (years)
Mean (SD) 5.3 (5.3) 4.2 (5.0) 6.2 (5.4)
Median (IQR) 3.2 (1.7–7.0) 2.6 (0.9–5.3) 5.3 (1.9–7.6) 0.11*
Children who developed a
first clinical event (%)
17 (50%) 4 (26.7%) 13 (68.4%) 0.04†
*Wilcoxon sum rank test.
†Fisher’s exact test.
RIS: radiologically isolated syndrome.
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administered for the index MRI, CSF appeared to be
more commonly obtained in children with one or
more enhancing lesion (6/21 (28.6%)) versus those
without enhancing lesions (1/18, (5.6%)), but this
result was not statistically significant (P=0.11).
Children who either did or did not have CSF
obtained did not differ in age or in the proportion
of children with index MRIs that met the 2005 MRI
criteria for dissemination in space (which requires
the most lesions of all the MRI dissemination in
space criteria).
A first clinical event occurred in 22 children
(36.1%) with a median of 1.7 (range 0.1–17.1)
years from index MRI (Tables 1 and 2). Table 3
shows the diagnostic indices of the different MRI
criteria for dissemination in space using the com-
plete case analysis of observed cases, both with
and without oligoclonal bands in CSF added, for
the subsequent development of a first clinical
event. The MAGNIMS 2016 criteria for dissemina-
tion in space differed from the 2005 criteria in sen-
sitivity (100% (95% CI 84.6–100%) vs. 72.7%
(95% CI 49.8–89.3%)), specificity (25.6% (95%
CI 13.0–42.1%) vs. 53.9% (95% CI 37.2–69.9%))
and NPV (100% (95% CI 69.2–100% vs. 77.8%
(95% CI 57.7–91.3%). PPV and accuracy were sim-
ilar (Table 3). The PPV of the 2010 and 2017 MRI
criteria for dissemination in space was 36.1% (95%
CI 24.0–48.1%), which is the same as the overall
proportion of children in the cohort that developed a
first clinical event. With the addition of oligoclonal
bands in CSF, the specificity of the 2016
MAGNIMS criteria increased to 72.7% (95% CI
49.8–89.3%) and the specificity of the 2005 criteria
increased to 83.3% (95% CI 58.6–96.4%). The
presence of oligoclonal bands alone had a sensitivity
of 76.5% (95% CI 50.1–93.2%) and a specificity of
64.7% (95% CI 38.3–85.8%). The overall ability of
the MAGNIMS 2016 criteria to discriminate
between children who either did or did not develop
a first clinical event, as measured by the AUC, also
significantly increased with the addition of oligoclo-
nal bands (P=0.03) with a similar statistical trend for
the 2005 criteria (P=0.16). All results were similar
when we removed the eight children who had been
exposed to a disease-modifying agent for MS. The
results from multiple imputation showed similar
findings (Supplemental Table 3).
Children with oligoclonal bands in CSF were more
likely to develop a first clinical event (Tables 1
and 2). In a multivariable model that also included
age, sex and exposure to a disease-modifying agent,
the presence of oligoclonal bands in the CSF
remained a statistically significant predictor
(complete case analysis: adjusted HR 4.1, 95% CI
1.1–14.4, P=0.03; multiple imputation: adjusted HR
3.0, 95% CI 1.1–8.5, P=0.04).
The presence of one or more spinal cord lesions on
the index MRI was the only individual component of
the different MRI criteria for dissemination in space
(Table 3) that was independently associated with an
increased risk of a first clinical event after adjusting
for age, sex and prior exposure to a disease-
modifying agent (complete case analysis: adjusted
HR 7.5, 95% CI 2.2–26.1, P=0.002; multiple impu-
tation: adjusted HR 4.7, 95% CI 1.4–15.8, P=0.012).
We could not calculate hazard ratios for one or more
periventricular lesions (only three or more), because
all 61 children in the cohort (100%) had at least one
periventricular lesion. No child had a lesion detected
in the optic nerve, but dedicated optic nerve sequen-
ces were not routinely obtained.
Discussion
The main findings of our study were that when used
alone in children with Ped-RIS, the 2016
MAGNIMS MRI criteria for dissemination in
space had greater sensitivity and NPV, but substan-
tially lower specificity than the 2005 MRI criteria
for dissemination in space, criteria that have been
used to define RIS in adults.1 When oligoclonal
bands in the CSF were added to the 2005 and
2016 MAGNIMS MRI criteria for dissemination in
space, the specificity of both increased.
The high sensitivity and NPV of the 2016
MAGNIMS MRI criteria for dissemination in
space may make them useful to identify children
with Ped-RIS at low risk of subsequently developing
a first clinical event (i.e. children who do not also
meet the 2016 MAGNIMS criteria may be at very
low risk of developing a first clinical event). A high
sensitivity also suggests that nearly all children who
will subsequently develop a first clinical event could
be identified with these criteria. However, the spe-
cificity of the 2016 MAGNIMS criteria was low,
which translates into a high number of false positive
results.
The greatest specificity was observed for the 2005
MRI criteria for dissemination space, with the addi-
tion of oligoclonal bands. High specificity reflects a
low false positive rate (that is a low rate of falsely
predicting that children will subsequently develop a
first clinical event). We believe that for RIS,
Makhani et al.
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especially in children, highly specific criteria are
desirable to minimise misdiagnosis, parental anxiety,
unnecessary testing and interventions that may have
side effects in children who actually are at low risk.
This is in contrast to symptomatic children with the
clinically isolated syndrome in whom highly sensi-
tive criteria may perhaps be preferable, so that a
diagnosis of MS may be made early to allow for
prompt treatment.
That the addition of oligoclonal bands improved the
specificity of MRI criteria for dissemination in space
in children with RIS has biological rationale.
Oligoclonal bands present in the CSF, but not
serum, reflect intrathecal antibody synthesis and
are often detected in children with established
MS.25,26 Even with the addition of oligoclonal
bands, the ability of the 2005 and 2016
MAGNIMS criteria to discriminate between children
who either did or did not subsequently develop a
first clinical event (as measured by the AUC)
remained modest, suggesting that additional bio-
markers may be needed.
Both the presence of oligoclonal bands in the CSF
and the presence of one or more asymptomatic
spinal cord lesions on MRI were independently asso-
ciated with an increased risk of a first clinical event,
findings that we reported previously in a subset of
this cohort.3 These results are similar to findings in
adults with RIS.2,27,28
Our study has some limitations. First, we analysed
data from a historical cohort of children with RIS for
whom clinical MRI protocols were not standardised.
All scans, however, employed standard sequences
for patients with MS. A prospective study using a
standardised MRI protocol is planned. We recognise
that there were variable follow-up times in our
cohort and that some children who have not yet dis-
played symptoms of MS may do so in the future. In
our statistical analyses, we used time-to-event sur-
vival analysis to account for this. Furthermore, we
examined the time-varying discriminating ability of
predictors across the follow-up time and did not
observe significant time trends. Not all children
had spinal cord imaging, optic nerve imaging or
analysis of CSF (i.e. there was missing data). In
order to overcome this limitation, we conducted sta-
tistical analyses both on the complete set of observed
cases and, to handle missing data, also followed up
with additional analyses based on multiple imputa-
tion, which yielded consistent results. Our study is of
modest size. However, RIS in children is rarely
diagnosed, and this is the only international longitu-
dinal study. While the analysis of additional CSF
biomarkers (e.g. neurofilament light chain) were
beyond the scope of this study, such markers could
be evaluated in the future.28 Because of our study
design, we could not calculate sensitivity and spe-
cificity for the 2010 or 2017 MRI criteria for dis-
semination in space. The assessment of these criteria
will require evaluation in other cohorts.
In summary, oligoclonal bands in the CSF improved
the specificity of both the 2005 and 2016
MAGNIMS MRI criteria for dissemination in
space in children with RIS. Specificity was greatest
for the 2005 criteria, used to define RIS in adults,
plus oligoclonal bands. We therefore propose that
when CSF is obtained in children with RIS, that
oligoclonal bands be tested to increase diagnostic
certainty. International collaborative prospective
studies are planned to develop evidence-based diag-
nostic criteria for RIS in children. Based on our
findings, we suggest that CSF biomarkers including
oligoclonal bands be evaluated. Improved diagnostic
criteria for RIS in children will enhance the classi-
fication of risk for the subsequent development of a
first clinical event. Accurately classifying the risk of
a first clinical event would help prevent unnecessary
interventions in children at low risk and identify
children at high risk for whom interventions such
as disease-modifying agents could be tested.
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